X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (1957) 1957
Book Review (221) 221
Publication (87) 87
Newsletter (26) 26
Newspaper Article (8) 8
Conference Proceeding (5) 5
Magazine Article (5) 5
Book Chapter (2) 2
Data Set (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
lansoprazole (1773) 1773
index medicus (1668) 1668
humans (1534) 1534
male (1152) 1152
female (987) 987
proton pump inhibitors (813) 813
adult (801) 801
middle aged (781) 781
omeprazole (757) 757
2-pyridinylmethylsulfinylbenzimidazoles (745) 745
omeprazole - analogs & derivatives (709) 709
gastroenterology & hepatology (673) 673
pharmacology & pharmacy (628) 628
aged (493) 493
omeprazole - administration & dosage (493) 493
helicobacter infections - drug therapy (465) 465
anti-ulcer agents - administration & dosage (435) 435
treatment outcome (416) 416
helicobacter pylori (410) 410
drug therapy, combination (369) 369
anti-ulcer agents - therapeutic use (350) 350
omeprazole - therapeutic use (339) 339
rabeprazole (292) 292
proton pump inhibitor (262) 262
gastroesophageal reflux - drug therapy (251) 251
amoxicillin - administration & dosage (250) 250
drug administration schedule (249) 249
pharmacokinetics (238) 238
clarithromycin - administration & dosage (234) 234
pantoprazole (218) 218
anti-bacterial agents - administration & dosage (217) 217
omeprazole - pharmacology (215) 215
animals (212) 212
proton pump inhibitors - administration & dosage (211) 211
2-pyridinylmethylsulfinylbenzimidazoles - administration & dosage (210) 210
dose-response relationship, drug (203) 203
double-blind method (202) 202
medicine & public health (200) 200
esomeprazole (198) 198
abridged index medicus (197) 197
adolescent (196) 196
prospective studies (195) 195
helicobacter pylori - drug effects (194) 194
infection (194) 194
gastroesophageal reflux (189) 189
anti-ulcer agents - pharmacology (176) 176
cross-over studies (175) 175
gastroesophageal-reflux disease (173) 173
proton pump inhibitors - therapeutic use (169) 169
administration, oral (165) 165
eradication (164) 164
time factors (159) 159
anti-bacterial agents - therapeutic use (154) 154
therapy (151) 151
aged, 80 and over (150) 150
hydrogen-ion concentration (150) 150
ranitidine (150) 150
drug interactions (149) 149
gastric acid - secretion (147) 147
2-pyridinylmethylsulfinylbenzimidazoles - therapeutic use (146) 146
clarithromycin (145) 145
amoxicillin (143) 143
efficacy (140) 140
double-blind (139) 139
rats (139) 139
management (137) 137
amoxicillin - therapeutic use (136) 136
triple therapy (136) 136
dosage and administration (135) 135
clarithromycin - therapeutic use (131) 131
omeprazole - adverse effects (131) 131
cytochrome p-450 cyp2c19 (128) 128
young adult (127) 127
enzyme inhibitors - administration & dosage (126) 126
internal medicine (125) 125
medicine, general & internal (125) 125
peptic ulcer - drug therapy (124) 124
omeprazole - pharmacokinetics (122) 122
anti-ulcer agents - adverse effects (121) 121
gastroenterology (121) 121
care and treatment (119) 119
proton pump inhibitors - pharmacology (115) 115
proton pump inhibitors - adverse effects (114) 114
erosive esophagitis (113) 113
gastroesophageal reflux disease (113) 113
drug therapy (109) 109
anti-ulcer agents - pharmacokinetics (105) 105
duodenal-ulcer (104) 104
genotype (103) 103
metronidazole - administration & dosage (103) 103
area under curve (100) 100
esophagitis (100) 100
intragastric ph (100) 100
gastric acidity determination (99) 99
pharmacology/toxicology (99) 99
helicobacter infections - complications (98) 98
disease (97) 97
aryl hydrocarbon hydroxylases - genetics (96) 96
follow-up studies (96) 96
oncology (96) 96
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (1873) 1873
Japanese (67) 67
French (14) 14
German (13) 13
Spanish (13) 13
Russian (9) 9
Chinese (3) 3
Korean (3) 3
Norwegian (2) 2
Czech (1) 1
Hungarian (1) 1
Swedish (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Gut, ISSN 0017-5749, 09/2016, Volume 65, Issue 9, pp. 1439 - 1446
ObjectiveThe objective of this study was to assess the efficacy, safety and tolerability of vonoprazan, a novel potassium-competitive acid blocker, as a... 
antibiotic therapy | clinical trials | Helicobacter pylori infection | helicobacter pylori - treatment | CLARITHROMYCIN | LANSOPRAZOLE | MULTICENTER | MANAGEMENT | CLINICAL-TRIAL | PHARMACOKINETICS | JAPAN | INFECTION | MONOFUMARATE TAK-438 | GASTROENTEROLOGY & HEPATOLOGY | AMOXICILLIN | Humans | Middle Aged | Helicobacter Infections - complications | Helicobacter pylori - drug effects | Male | Drug Monitoring - methods | Proton Pump Inhibitors - administration & dosage | Pyrroles - administration & dosage | Helicobacter Infections - drug therapy | Clarithromycin - administration & dosage | Metronidazole - adverse effects | Peptic Ulcer - diagnosis | Pyrroles - adverse effects | Adult | Female | Amoxicillin - administration & dosage | Anti-Bacterial Agents - adverse effects | Helicobacter Infections - diagnosis | Lansoprazole - administration & dosage | Proton Pump Inhibitors - adverse effects | Double-Blind Method | Drug Administration Schedule | Clarithromycin - adverse effects | Metronidazole - administration & dosage | Treatment Outcome | Drug Therapy, Combination - methods | Lansoprazole - adverse effects | Sulfonamides - adverse effects | Amoxicillin - adverse effects | Helicobacter pylori - isolation & purification | Anti-Bacterial Agents - administration & dosage | Peptic Ulcer - drug therapy | Breath Tests - methods | Peptic Ulcer - etiology | Sulfonamides - administration & dosage | Usage | Safety and security measures | Research | Helicobacter pylori | Antacids | Index Medicus | Abridged Index Medicus | Helicobacter Pylori | HELICOBACTER PYLORI - TREATMENT | CLINICAL TRIALS | 1506 | ANTIBIOTIC THERAPY | HELICOBACTER PYLORI INFECTION
Journal Article
Lancet, The, ISSN 0140-6736, 2016, Volume 388, Issue 10058, pp. 2355 - 2365
Summary Background Whether concomitant therapy is superior to bismuth quadruple therapy or 14-day triple therapy for the first-line treatment of Helicobacter... 
Internal Medicine | CLARITHROMYCIN | ESOMEPRAZOLE | MEDICINE, GENERAL & INTERNAL | METAANALYSIS | EFFICACY | GASTRIC-CANCER | RESISTANCE | SEQUENTIAL THERAPY | INFECTION | ERADICATION | METRONIDAZOLE | Humans | Middle Aged | Helicobacter pylori - drug effects | Male | Antacids - therapeutic use | Anti-Bacterial Agents - therapeutic use | Proton Pump Inhibitors - administration & dosage | Metronidazole - therapeutic use | Helicobacter Infections - drug therapy | Clarithromycin - administration & dosage | Organometallic Compounds - therapeutic use | Female | Urea - metabolism | Amoxicillin - administration & dosage | Lansoprazole - administration & dosage | Drug Administration Schedule | Metronidazole - administration & dosage | Breath Tests | Tetracycline - therapeutic use | Clarithromycin - therapeutic use | Proton Pump Inhibitors - therapeutic use | Amoxicillin - therapeutic use | Taiwan | Drug Therapy, Combination - statistics & numerical data | Lansoprazole - therapeutic use | Antacids - administration & dosage | Anti-Bacterial Agents - administration & dosage | Tetracycline - administration & dosage | Organometallic Compounds - administration & dosage | Clinical trials | Medical colleges | Helicobacter infections | Care and treatment | Helicobacter pylori | Antiulcer drugs | Analysis | Bacteria | Bacterial infections | Antibiotics | Drug resistance | Drug therapy | Index Medicus | Abridged Index Medicus
Journal Article
Lancet, The, ISSN 0140-6736, 2013, Volume 381, Issue 9862, pp. 205 - 213
Journal Article
American Journal of Gastroenterology, ISSN 0002-9270, 07/2016, Volume 111, Issue 7, pp. 949 - 956
Journal Article
Lancet, The, ISSN 0140-6736, 2011, Volume 378, Issue 9790, pp. 507 - 514
Journal Article
Gut, ISSN 0017-5749, 11/2016, Volume 65, Issue 11, pp. 1784 - 1792
ObjectiveSignificant heterogeneity was observed in previous trials that assessed the efficacies of sequential therapy for 10 days (S10) versus triple therapy... 
MULTICENTER | METAANALYSIS | MANAGEMENT | EFFICACY | DRUG THERAPY | RESISTANCE | INFECTION | GASTROENTEROLOGY & HEPATOLOGY | Humans | Hospitalization - statistics & numerical data | Helicobacter pylori - drug effects | Male | Drug Monitoring - methods | Proton Pump Inhibitors - administration & dosage | Helicobacter Infections - drug therapy | Clarithromycin - administration & dosage | Metronidazole - adverse effects | Adult | Female | Amoxicillin - administration & dosage | Anti-Bacterial Agents - adverse effects | Helicobacter Infections - diagnosis | Lansoprazole - administration & dosage | Proton Pump Inhibitors - adverse effects | Drug Administration Schedule | Clarithromycin - adverse effects | Metronidazole - administration & dosage | Treatment Outcome | Drug Therapy, Combination - methods | Lansoprazole - adverse effects | Amoxicillin - adverse effects | Ambulatory Care - statistics & numerical data | Helicobacter pylori - isolation & purification | Anti-Bacterial Agents - administration & dosage | Breath Tests - methods | Helicobacter Infections - microbiology | Hospital patients | Care and treatment | Usage | Helicobacter pylori | Therapeutics | Research | Health aspects | Homeopathy | Materia medica and therapeutics | Index Medicus | Abridged Index Medicus | Helicobacter Pylori | HELICOBACTER PYLORI - TREATMENT | 1506 | ANTIBIOTIC THERAPY
Journal Article
Clinical Pharmacology & Therapeutics, ISSN 0009-9236, 01/2011, Volume 89, Issue 1, pp. 65 - 74
Four randomized, placebo‐controlled, crossover studies were conducted among 282 healthy subjects to investigate whether an interaction exists between... 
VARIABILITY | LANSOPRAZOLE | RABEPRAZOLE | THERAPY | CARDIOVASCULAR EVENTS | STENT PLACEMENT | PHARMACOLOGY & PHARMACY | OUTCOMES | ANTIPLATELET ACTION | PROTON-PUMP INHIBITORS | DRUG-INTERACTION | Proton Pump Inhibitors - pharmacology | Ticlopidine - pharmacology | Humans | Middle Aged | Half-Life | Male | 2-Pyridinylmethylsulfinylbenzimidazoles - pharmacology | Enzyme Inhibitors - administration & dosage | Platelet Aggregation Inhibitors - blood | Young Adult | Drug Interactions | Proton Pump Inhibitors - administration & dosage | Platelet Aggregation Inhibitors - pharmacology | Adult | Female | Omeprazole - pharmacology | Platelet Aggregation - drug effects | Platelet Aggregation Inhibitors - pharmacokinetics | Ticlopidine - pharmacokinetics | Enzyme Inhibitors - adverse effects | Proton Pump Inhibitors - adverse effects | Aryl Hydrocarbon Hydroxylases - antagonists & inhibitors | Double-Blind Method | Drug Administration Schedule | 2-Pyridinylmethylsulfinylbenzimidazoles - adverse effects | Omeprazole - administration & dosage | Enzyme Inhibitors - pharmacology | Omeprazole - adverse effects | Ticlopidine - analogs & derivatives | Cross-Over Studies | Prodrugs - adverse effects | Prodrugs - pharmacokinetics | Cytochrome P-450 CYP2C19 | Platelet Activation - drug effects | 2-Pyridinylmethylsulfinylbenzimidazoles - administration & dosage | Prodrugs - pharmacology | Ticlopidine - blood | Omeprazole | Pantoprazole | Drug interactions | Analysis | Dosage and administration | Research | Patients | Health aspects | Index Medicus | Abridged Index Medicus
Journal Article
Journal Article
Gastroenterology, ISSN 0016-5085, 2017, Volume 152, Issue 1, pp. 134 - 141
Journal Article
Stroke, ISSN 0039-2499, 03/2015, Volume 46, Issue 3, pp. 722 - 731
BACKGROUND AND PURPOSE—There is controversy and little information about whether individual proton pump inhibitors (PPIs) differentially alter the... 
LANSOPRAZOLE | drug interactions | PROPENSITY SCORE | CARDIOVASCULAR EVENTS | CORONARY | OMEPRAZOLE | stroke | CLINICAL NEUROLOGY | pharmacoepidemiology | proton pump inhibitors | CONCOMITANT USE | platelet aggregation inhibitors | cohort studies | PERIPHERAL VASCULAR DISEASE | HEALTHY-VOLUNTEERS | OUTCOMES | Medicaid | JAPANESE PATIENTS | ARTERY-DISEASE | Rabeprazole - adverse effects | Esomeprazole - administration & dosage | Humans | Middle Aged | Esomeprazole - adverse effects | Male | Risk | Drug Therapy, Combination - adverse effects | Stroke - chemically induced | Proton Pump Inhibitors - administration & dosage | Aged, 80 and over | Ticlopidine - administration & dosage | Female | Stroke - epidemiology | Retrospective Studies | Brain Ischemia - chemically induced | Lansoprazole - administration & dosage | Proton Pump Inhibitors - adverse effects | Data Interpretation, Statistical | Stroke - prevention & control | 2-Pyridinylmethylsulfinylbenzimidazoles - adverse effects | Omeprazole - administration & dosage | Proportional Hazards Models | Omeprazole - adverse effects | Brain Ischemia - prevention & control | Ticlopidine - analogs & derivatives | Lansoprazole - adverse effects | Aged | 2-Pyridinylmethylsulfinylbenzimidazoles - administration & dosage | Rabeprazole - administration & dosage | Index Medicus | Pharmacoepidemiology | Stroke | Drug interactions | Cohort studies | Platelet aggregation inhibitors | Proton pump inhibitors
Journal Article
Journal Article